• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于靶点的计算机筛选法对不同的表观遗传学靶点进行分析,以寻找治疗乳腺癌的有效药物。

Target-based in-silico screening of basil polysaccharides against different epigenetic targets responsible for breast cancer.

机构信息

Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab, India.

Department of Research and Development, Lovely Professional University, Phagwara, Punjab, India.

出版信息

J Recept Signal Transduct Res. 2022 Oct;42(5):521-530. doi: 10.1080/10799893.2022.2058016. Epub 2022 Jul 21.

DOI:10.1080/10799893.2022.2058016
PMID:35862239
Abstract

PURPOSE

Breast cancer (BC) is one of the leading types of cancer found in women. One of the causes reported for BC is improper regulation of epigenetic modifications. Various epigenetic targets such as histone deacetylases (HDAC) and histone acetyltransferases (HAT) regulate many types of cancer, including BC. Basil is known to possess anti-cancer properties; however, the role of its polysaccharides against different epigenetic targets is still not very clear. Therefore, the molecular docking method is used to find out the binding potential of the BPSs against different epigenetic targets responsible for BC.

METHODS

All the basil polysaccharides (BPSs) were screened against the diverse epigenetic targets reported for BC (HDAC1-2, 4-8, and HAT) using molecular docking studies alongwith swissADME studies to check the drug likeliness of the BPSs.

RESULTS

It was found that glucosamine ring, glucosamine linear, glucuronic acid linear, rhamnose linear, glucuronic acid ring, galactose ring, mannose, glucose, and xylose were exhibited consistent binding potential against the epigenetic targets (HDAC1, HDAC2, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HAT,) responsible for BC.

CONCLUSION

This is the first report where BPSs were reported against these epigenetic targets. These studies can help to understand the underlying mechanism of BPSs used against epigenetic targets for BC. These results can be further validated experimentally to confirm their potential as a promising inhibitor against the epigenetic targets (HDAC1-2, 4-8, and HAT) having a role in BC.

摘要

目的

乳腺癌(BC)是女性中最常见的癌症类型之一。据报道,BC 的一个病因是表观遗传修饰的不当调节。各种表观遗传靶点,如组蛋白去乙酰化酶(HDAC)和组蛋白乙酰转移酶(HAT),调节着包括 BC 在内的多种癌症。罗勒被认为具有抗癌特性;然而,其多糖针对不同的表观遗传靶点的作用尚不清楚。因此,本研究采用分子对接方法,找出 BPSs 与负责 BC 的不同表观遗传靶点的结合潜力。

方法

采用分子对接研究,筛选出所有罗勒多糖(BPSs)与报道的针对 BC 的不同表观遗传靶点(HDAC1-2、4-8 和 HAT)进行筛选,并结合 swissADME 研究,检查 BPSs 的药物相似性。

结果

发现葡糖胺环、葡糖胺线性、葡萄糖醛酸线性、鼠李糖线性、葡萄糖醛酸环、半乳糖环、甘露糖、葡萄糖和木糖对负责 BC 的表观遗传靶点(HDAC1、HDAC2、HDAC4、HDAC5、HDAC6、HDAC7、HDAC8 和 HAT)表现出一致的结合潜力。

结论

这是首次报道 BPSs 针对这些表观遗传靶点。这些研究有助于了解 BPSs 针对表观遗传靶点用于 BC 的潜在机制。这些结果可以通过进一步的实验验证来确认它们作为针对在 BC 中起作用的表观遗传靶点(HDAC1-2、4-8 和 HAT)的有前途的抑制剂的潜力。

相似文献

1
Target-based in-silico screening of basil polysaccharides against different epigenetic targets responsible for breast cancer.基于靶点的计算机筛选法对不同的表观遗传学靶点进行分析,以寻找治疗乳腺癌的有效药物。
J Recept Signal Transduct Res. 2022 Oct;42(5):521-530. doi: 10.1080/10799893.2022.2058016. Epub 2022 Jul 21.
2
Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.羟肟酸衍生物作为 HDAC1、HDAC6 和 HDAC8 的抑制剂,对癌细胞系具有抗增殖活性。
Sci Rep. 2020 Jun 26;10(1):10462. doi: 10.1038/s41598-020-67112-4.
3
Epigenetic therapy of cancer with histone deacetylase inhibitors.用组蛋白去乙酰化酶抑制剂进行癌症的表观遗传治疗。
J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78. doi: 10.4103/0973-1482.137937.
4
Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.尿路上皮癌中组蛋白去乙酰化酶(HDAC)表达模式的改变和 HDAC 抑制剂的活性。
Urol Oncol. 2013 Nov;31(8):1770-9. doi: 10.1016/j.urolonc.2012.06.015. Epub 2012 Sep 1.
5
The clinical significance of histone deacetylase-8 in human breast cancer.组蛋白去乙酰化酶-8 在人乳腺癌中的临床意义。
Pathol Res Pract. 2021 Apr;220:153396. doi: 10.1016/j.prp.2021.153396. Epub 2021 Mar 1.
6
The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.组蛋白去乙酰化酶抑制剂的结构要求:C4修饰的SAHA类似物具有HDAC6/HDAC8双重选择性。
Eur J Med Chem. 2018 Jan 1;143:1790-1806. doi: 10.1016/j.ejmech.2017.10.076. Epub 2017 Oct 31.
7
Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.强效帕比司他(panobinostat)组蛋白去乙酰化酶抑制剂衍生物的设计:提高 HDAC2 和 HDAC8 之间同工酶选择性的分子考虑。
Mol Inform. 2019 Mar;38(3):e1800080. doi: 10.1002/minf.201800080. Epub 2018 Oct 22.
8
Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.组蛋白表观遗传调节剂在乳腺癌中的诊断和治疗意义。
Expert Rev Mol Diagn. 2016;16(5):541-51. doi: 10.1586/14737159.2016.1156534. Epub 2016 Mar 16.
9
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.HDAC8通过维持Notch1蛋白稳定性调控乳腺癌干细胞的非表观遗传功能。
Oncotarget. 2016 Jan 12;7(2):1796-807. doi: 10.18632/oncotarget.6427.
10
The role of histone deacetylase 3 in breast cancer.组蛋白去乙酰化酶 3 在乳腺癌中的作用。
Med Oncol. 2022 May 17;39(5):84. doi: 10.1007/s12032-022-01681-4.